虽然海吉亚医疗发出盈警，但相信业绩下滑已基本触底。当中，下半年营收同比料跌2%至约20亿元人 民币，而非国际财务报告准则经调整净利润恢复3%正增长，显示盈利韧性正在提升;经调整净利润趋稳 是营运执行力提升的积极讯号。 里昂发布研报称，展望2026年，海吉亚医疗(06078)关键增长动力包括扩张非国家医保目录收入、提升 现有医院利用率，以及降低负债率以推动经营杠杆来重建利润率。该行维持海吉亚医疗的"跑赢大市"评 级，但将目标价由17港元下调至15.9港元。 ...

虽然海吉亚医疗发出盈警，但相信业绩下滑已基本触底。当中，下半年营收同比料跌2%至约20亿元人 民币，而非国际财务报告准则经调整净利润恢复3%正增长，显示盈利韧性正在提升; 经调整净利润趋稳 是营运执行力提升的积极讯号。 智通财经APP获悉，里昂发布研报称，展望2026年，海吉亚医疗(06078)关键增长动力包括扩张非国家医 保目录收入、提升现有医院利用率，以及降低负债率以推动经营杠杆来重建利润率。该行维持海吉亚医 疗的"跑赢大市"评级，但将目标价由17港元下调至15.9港元。 ...

证券之星消息，2月2日南向资金减持46.02万股海吉亚医疗（06078.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持154.04万股。近20个交易日中，获南向资金减持的有15天，累计净减持651.92 万股。截至目前，南向资金持有海吉亚医疗（06078.HK）2.02亿股，占公司已发行普通股的32.59%。 海吉亚医疗控股有限公司是一家主要提供医疗服务的投资控股公司。该公司通过两个业务部门开展业 务。医院业务分部从事提供肿瘤一站式综合诊疗服务，围绕肿瘤核心业务开展多学科医疗服务，包括提 供医疗放疗、化疗、手术、靶向在内的多重肿瘤医疗服务，逐步覆盖癌症诊断、治疗与康复等各阶段。 其它业务分部主要从事其他业务。该公司主要在国内市场经营其业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Market Performance - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 2.23% to 26,775.57 points, and the Hang Seng Tech Index dropping by 3.36% to 5,526.31 points [1] - Major technology stocks saw significant losses, including Alibaba down 3.49%, Tencent down 1.24%, and JD.com down 1.69% [1] - Gold and silver prices fell sharply, with Shandong Gold and Chifeng Gold both dropping over 12% [1] Company Earnings Forecasts - Haiprime (09989.HK) expects a net profit of 284 million to 377 million yuan for 2025, a decrease of 41.71% to 56.09% year-on-year [2] - Datang Power (00991.HK) anticipates a net profit of approximately 6.8 billion to 7.8 billion yuan for 2025, an increase of about 51% to 73% year-on-year [6] - Longhua Automobile (02333.HK) projects total revenue of 222.79 billion yuan for 2025, a year-on-year growth of 10.19% [4] - CICC (03908.HK) forecasts a net profit of 8.542 billion to 10.535 billion yuan for 2025, an increase of 50% to 85% year-on-year [5] Company Warnings - Kaisa New Energy (01108.HK) issued a profit warning, expecting a net loss increase of approximately 90.07 million to 290 million yuan for 2025 [7] - Xinyi Alloy (00505.HK) also issued a profit warning, anticipating a 50% decrease in profit attributable to equity shareholders for 2025 [8] - Fudan Zhangjiang (01349.HK) expects a net loss of approximately 120 million to 180 million yuan for 2025 [9] Strategic Developments - Innovation Intelligence (02121.HK) signed a strategic cooperation agreement with Shanghai Jiao Tong University Hainan Research Institute [11] - Zhonghui Biotech-B (02627.HK) received approval from the National Medical Products Administration for its trivalent influenza virus subunit vaccine [12]

Group 1 - Hai Jiaya Medical (06078.HK) saw a rise of over 4%, with a current increase of 4.13%, trading at HKD 13.35 [2] - The trading volume reached HKD 62.3713 million [2]

Core Viewpoint - Haijia Medical (06078) anticipates a decline in revenue and net profit for 2025, primarily due to goodwill impairment and increased operational costs [1][4] Financial Projections - Expected revenue for 2025 is approximately RMB 4.0–4.5 billion, representing a year-on-year decrease of about 9% to 10% [1][4] - Projected net profit is around RMB 140–200 million, reflecting a year-on-year decline of approximately 66% to 76% [1][4] - Adjusted net profit is estimated to be between RMB 450–490 million, down about 19% to 25% year-on-year [1][4] - Cash generated from operating activities is expected to be around RMB 940–1,000 million, showing an increase of approximately 33% to 41% year-on-year [1][4] Factors Influencing Financial Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation for newly opened hospitals [1][4] - The net profit decrease is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1][4] - The company has conducted a careful assessment of its operational and financial performance, as well as future business prospects, to determine the necessity and amount of the impairment and provision [1][4]

公告称，收入、净利润及非国际财务报告准则经调整净利润下降主要是由于行业及宏观经济影响，以及 集团新开业医院开办费及折旧摊销增加的影响。集团截至2025年12月31日止年度的净利润下降除了上述 因素外，还主要由于Etern Group Ltd.的商誉减值拨备。于厘定有关减值及拨备的必要性及金额时，公司 已仔细评估集团的营运及财务表现以及其业务的未来前景。实际减值及拨备金额仍须待公司进一步评估 后方可作实。 智通财经APP获悉，海吉亚医疗(06078)涨超4%，截至发稿，涨4.13%，报13.35港元，成交额6237.13万 港元。 消息面上，海吉亚医疗公布，预期2025年的收入约为人民币40.0–40.5亿元，同比下降约9%至10%；净 利润约为人民币1.4–2.0亿元，同比下降约66%至76%(主要受商誉减值影响)；经调整净利润约为人民币 4.5–4.9亿元，同比下降约19%至25%；经营活动所得现金净额约为人民币9.4–10.0亿元，同比增加约33% 至41%。 ...

Core Viewpoint - Haijia Medical (06078) shares rose over 4%, currently up 4.13% at HKD 13.35, with a trading volume of HKD 62.37 million [1] Financial Projections - The company expects revenue for 2025 to be approximately RMB 4.0–4.05 billion, representing a year-on-year decline of about 9% to 10% [1] - Net profit is projected to be around RMB 140–200 million, reflecting a year-on-year decrease of approximately 66% to 76%, primarily due to goodwill impairment [1] - Adjusted net profit is anticipated to be between RMB 450–490 million, indicating a year-on-year decline of about 19% to 25% [1] - Cash generated from operating activities is expected to be around RMB 940–1,000 million, showing a year-on-year increase of approximately 33% to 41% [1] Factors Influencing Financial Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation for newly opened hospitals [1] - The decrease in net profit for the year ending December 31, 2025, is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1] - The company has conducted a careful assessment of its operational and financial performance, along with future business prospects, to determine the necessity and amount of the impairment and provision [1]

格隆汇1月30日｜海吉亚医疗发布公告披露，公司2025年下半年实现收入、就诊人次双环比增长，经营 面迎来边际改善；全年经营性现金流预计在人民币9.4亿元至10亿元区间，同比增幅约33%至41%。同 时，公司运营质量持续夯实，2025年末银行债务净减少3.4亿元，全年资本开支同比下降16%至24%；伴 随在建工程项目陆续收尾，公司未来资本开支规模有望进一步压降。表观净利润有所下降主要为商誉减 值影响，该等减值及拨备为一次性会计调整且无实际现金流出。 ...

Core Viewpoint - Haijia Medical announced that it expects to achieve a quarter-on-quarter increase in revenue and patient visits in the second half of 2025, indicating marginal improvement in operations [1] Financial Performance - The company's operating cash flow for the year is projected to be between RMB 940 million and RMB 1 billion, representing a year-on-year growth of approximately 33% to 41% [1] - The net bank debt is expected to decrease by RMB 340 million by the end of 2025, while capital expenditures are anticipated to decline by 16% to 24% year-on-year [1] Operational Quality - The company is solidifying its operational quality, with ongoing construction projects nearing completion, which is likely to further reduce future capital expenditure [1] - The apparent net profit has decreased primarily due to goodwill impairment, which is a one-time accounting adjustment and does not involve actual cash outflow [1]